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ABSTRACT 
The term 'dual diagnosis' denotes the coexistence of substance use disorder(s) and other, 
non-substance-use, psychiatric disorder(s). The last two decades, and especially the 1990s, have 
witnessed tremendous research and clinical interest in this previously neglected area. India, however, 
lags behind, inspite of indications that the problem exists here too. The current approach to managing 
such patients is the 'integrated treatment model' in which the same clinician (or team of clinicians) 
provides treatment for both the disorders at the same time, treating both with equal understanding 
and importance. Both pharmacotherapy as well as psychosocial therapies are specifically designed 
keeping in mind the integrated' philosophy of treatment. The specific principles and components 
are described Areas of difficulty, uncertainty, and future considerations are highlighted, with a note 
on the Indian setting. 
Key words Diagnosis, dual (psychiatry), management 
The term 'dual diagnosis' is a broad term 
that indicates the simultaneous presence of two 
independent medical disorders This is based on 
the concept of comorbidity' and, in its broadest 
sense, the two terms are synonymous. However, 
for the last two decades or so, within the fields 
of mental health, psychiatry and addiction 
medicine, the term "dual diagnosis" has been 
popularly used to describe the coexistence of 
substance use disorder(s) and other psychiatric 
disorder(s) Ries (1995) listed various other 
equivalent terms denoting the same 
combination dual disorder, mentally ill chemical 
abusers (MICA), mentally ill substance abusers 
(MISA), chemical abuse and mental illness 
(CAMI) and substance abusing mentally ill 
(SAMI) Of all these similar sounding names, 
the term dual diagnosis' seems to have survived 
the best In fact, the National Library of Medicine, 
Washington, D C , while publishing their Medical 
Subject Headings (MeSH) for both Index 
Medicus and MEDLINE, introduced the term 
"Diagnosis, dual (psychiatry)" for the first time 
in 1994, keeping in view the increasingly large 
number of publications in this area (earlier, these 
papers used to be cited under the broad umbrella 
term of comorbidity' that included all possible 
comorbid conditions and notjust dual diagnosis' 
as we understand it now). Uptill August, 1999, 
there were 525 references under this MeSH 
alone, i.e., about a hundred indexed publications 
a year! (A manual search reveals more articles, 
both in indexed and non-indexed journals). This 
is just one indicator of the growing importance 
of this topic in the recent years. 
Given this background, it is surprising 
to note the near-absence of relevant published 
scientific material from India. Is it due to lack of 
the problem or to lack of the awareness of the 
problem? The scanty literature available from 
India (reviewed later) argue against the first 
possibility Lack of awareness may be a more 
plausible reason The initial spurt of research in 
this area came from the USA, followed by 
gradually spreading awareness (and research) 
from Canada, Mexico, South America, Australia, 
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Europe and UK (Johnson, 1997; Hall & Farell, 
1997; Heather & Gilvarry,1998; Krausz et al., 
1999). It is time that Indian researchers in the 
area of mental health and substance abuse also 
woke up to the reality and to meet the challenge. 
This review article aims to contribute to the 
awakening of this interest. 
EPIDEMIOLOGY 
To date, numerous epidemiological 
studies have been carried out on dual diagnosis 
(Regier et al.,1990; Kessler et al.,1996, 1997; 
Mankangas et al.,1998; Bucholz,1999; Dixon, 
1999) These studies have been carried out on 
two types of population i.e. 'general' and 'clinic-
based'. It, however, needs to be emphasized here 
that the wealth of data in relation to prevalence 
and patterns emanates from the USA. 
USA based rates 
General population studies have 
reported slightly varying life time rates of 
comorbidity - 60% (Regier et al.,1990) to 79% 
(Kessler, 1995), the patterns of comorbidity, 
however, show strong agreement. 
The ECA study (Regier et al.,1990) 
found high odds ratios for lifetime comorbidity 
for antisocial personality disorder, bipolar 
disorder, and schizophrenia in males; for phobias 
and depressive disorders in females. Similar 
trends have been seen in the National 
Comorbidity Survey (Kessler et al.,1996, 1997). 
On the other hand, clinic-based studies 
have reported very high rates in psychiatry 
settings (ranging from 23-80%), but values are 
on the lower side in addiction settings i.e. 0.6-
6% (Miller & Fine, 1993). The discrepancy is due 
to different referral and intake patterns. 
European rates 
Studies are mostly on patients with 
psychosis/schizophrenia with rates ranging from 
22% (Duke et al.,1994) to 43% (Soyka et al., 
1993). A latest study on a clinic sample of opioid 
addicts found 51% to have at least one non-
substance related psychiatric disorder, the 
commoner ones being phobic disorder, other 
anxiety disorders, and depressive episodes 
(Krausz et al., 1999). 
Indian rates 
The earliest study from India is also, 
interestingly, the only general population study 
so far (Dube & Handa, 1971). In a house-to-house 
interview-based survey of 16,725 persons in and 
around Agra, it was found that alcohol and drug 
abuse (defined as regular use for more than a 
year) occurred in 4.6% of the 560 mentally ill 
persons, compared to 2.2% of the non-psychiatric 
population (i.e., dual diagnosis was doubly 
prevalent compared to the base rate of substance 
abuse). The prevalences of substance abuse 
amongst various psychiatric categories were, in 
descending order, manic-depressive illness 
(16%), schizophrenia (14%), organic psychosis 
(5%), and neurotic and other disorders (2%). Two 
other earlier studies focussed on rates of 
substance abuse in hospital-attending patients : 
one found 23.6% cannabis abuse in 566 
consecutive mental hospital admissions (Dube et 
al.,1975) and the other found 16.4% of substance 
abuse in 1000 male psychiatric outpatients 
(Trivedi & Sethi, 1978). Rates were generally 
higher in affective disorder and schizophrenia. 
More recent studies have structured and 
standardized interview schedules. Mahajan 
(1993) found lifetime prevalence of psychiatric 
disorders being 50% in 30 opioid users and 56.6% 
in 30 alcoholics attending a de-addiction centre; 
personality disorders were the commonest and 
more in opioid users. Kishore et al.(1994) reported 
a lifetime prevalence rate of 60.5% in opioid 
abusers and alcoholics. Sokhlet & Sharma (1998) 
found high rates of depression and antisocial 
personality disorder (ASPD) in heroin users while 
Sattar et al.( 1998) found a prevalence rate of 29% 
in alcoholics. All these rates are considerably 
higher than those in the three earlier studies, which 
may reflect a higher general prevalence of 
substance use over the years. However, the dual 
diagnosis rates were higher even in the early 
studies, considering a much lower prevalence of 
substance abuse in the general population then 
(e.g. 2.2% in Dube & Handa. 1971). 
Interestingly, there is only one study 
(Reddy & Prassana,1998) which assessed 
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comorbidity of anxiety disorders rather than 
psychosis or severe mental illness in alcoholics. 
The authors reported presence of phobias, 
generalized anxiety disorder and panic disorder 
(in decreasing order of occurrence) amongst the 
alcoholics. 
Hence, it can be seen from the above data 
that presence of comorbidity is prevalent to a 
significant degree for which treatment assumes 
paramount importance. But, why at all should 
comorbidity (or dual diagnosis) assume such 
great importance? Why cannot the two (or more) 
co-occurring disorders be treated as per the 
guidelines for each of the individual disorder? 
NEED FOR SPECIAL FOCUS ON MANAGEMENT 
There are certain factors which necessitate 
the need to focus on the management of dual-
disorder patients 
The patient related factors are-such 
persons generally belong to lower socio-
economic strata (Kay et al.,1989). They have a 
positive family history of sociopathy or 
alcoholism leading to a disruptive and chaotic 
environment (Kay et al.,1989), with increased 
risk for serious acts of violence (Scott et al., 
1998) Poor adjustment (Bartels et al.,1993) 
leads to increased risk for homelessness (Drake 
& Wallach,1989) Also, such patients are hostile 
and uninterested in mental health services 
(Ziedoms 8. Trudeau.1997), indulge in illegal 
activities (Johnson,1997), show lack of 
responsibility with less concern of societal and 
moral values (Kay et al.,1989) which leads to 
poorer compliance (Bartels et al.,1993; Kosten 
& Ziedonis,1997; Newman et al ,1998) and 
symptomatic worsening (Dixon.1999). 
Treatment and outcome issues related to 
dual diagnosis also influence the need for 
comprehens've management Such patients get 
hospitalized at an early age (Kay et al.,1989), 
with longer duration of illness (Hall & Farrell, 
1997) and frequent relapse and hospitalizations 
(Johnson, 1997. Tomassan & Vaglum,1998). 
They present very frequently to emergency 
services (Bartels et al .1993) leading to higher 
treatment costs (Johnson, 1997). Also, they are 
frequently incarcerated for legal violations 
(Safer, 1987) and generally have poorer outcome 
(Hall & Farrell, 1997; Dixon,1999). 
The physician (psychiatrist) related factors 
that make management difficult are : (1) mental 
health providers often refuse to treat such 
patients until they accept treatment for their 
substance abuse and achieve sobriety (Harrison 
et al.,1985); (2) conversely, substance abuse 
therapists frequently exclude the mentally ill 
because of their difficult behaviour or because 
their use of psychotropics is seen as substituting 
one addiction for another (Harrison et al.,1985); 
and, finally (3) guidelines for treatment aspects 
i.e. appropriateness of sequential treatment, 
choice of sequence, value of pharmacotherapies, 
timing and enforcement of abstinence during 
treatment are mostly unclear and arbitrary 
(Kofoed et al.,1986; Goldsmith, 1999). 
CONTROVERSIES IN MANAGEMENT ISSUES 
1. Which disorder should be considered more 
important for purposes of treatment - psychiatric 
or substance use? 
2. Which setting is to be preferred for treatment 
-psychiatric v/s de-addiction; outpatient v/s 
inpatient? 
3. What are the ideal components or principles 
of therapy? 
4. Who should ideally treat such patients -
psychiatrist or de-addiction specialist? 
5. What all treatment personnel are needed? 
6. Who assumes the funding and administrative 
responsibility? 
7. Is integration of psychiatric and de-addiction 
treatment services possible? 
8. Are the services provided comprehensive, 
effective and cost-efficacious? 
An attempt will now be made to address 
these controversies by reviewing the 
considerations and consensus achieved in this 
area till now But before that, it is important to 
understand what systems (or models') currently 
exist for management of such patients, their 
deficits in providing the answers to the above 
questions, and hence the need for an ' integrated' 
model (Ries,1993; Mueser et al.,1997, 1998a; 
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Drake et al.,1998a; el Mallakh,1998; Mercer et 
al.,1998; Siegfried, 1998; Goldsmith, 1999). 
EXISTING MODELS OF MANAGEMENT 
Serial (or sequential) Model 
By definition, one treatment (either 
psychiatric or addiction) modality is followed by 
the other. 
It is advantageous in that it allows the 
chemical dependency and mental health system 
to exist separately, personnel are not required 
to learn new skills or change basic concepts, 
billing, administrative and treatment facilities 
remain separate, is coherent with the previous 
model of separation of treatment system and is 
consistent with the administrative structure. 
However, the disadvantages associated 
with this system are that it cannot address 
individual patient needs, patients are frequently 
provided with contradictory information, 
explanations and therapies, there are chances 
of numerous potential conflicts with little scope 
for resolution of the same, and it requires 
different treating teams to know about the 
treatment plans of each other. Most importantly, 
this serial treatment approach becomes a 
common clinical justification for exclusion from 
treatment rather than an explicit treatment 
model. In this approach, dually diagnosed 
patients are told they are not eligible for 
treatment in one part of a system until they 
resolve the other problem first (Mueser et 
al.,1998a); thus, "the schizophrenic with 
alcoholism might not be admitted to either a pure 
psychiatric unit or a pure chemical dependency 
unit because of being too psychotic for the latter 
or too intoxicated for the former unit" (Ries, 
1993) This approach rigidly defends programme 
boundaries while ignoring individual patients and 
larger systems needs; the patient often keeps 
on shuttling between the psychiatric and the de-
addiction units without any tangible relief in either 
of his problems due to this unfortunate process 
derisively dubbed as "ping-pong therapy" (Osher 
& Kofoed.1989). 
Parallel Model 
By definition, there is concurrent but 
separate treatment of both psychiatric disorders 
and addictive disorders. 
Its advantages are that it does not require 
large administrative and system changes, and, 
perhaps, starts to force integration of the concepts 
of different treatments thereby creating less 
conceptual conflicts in the patient. In theory, this 
should work well. In practice, however, such 
conceptual integration between the two parallel 
components of treatment rarely occurs, and "the 
burden of integration has either fallen on the 
patient, or, more likely, has not occurred at all" 
(Mueser et al., 1998a). For example, the use of 
affectively charged, confrontational approaches 
has been common among substance abuse 
treatment providers, while that may be 
unproductive or even counterproductive when 
working with patients with severe mental illnesses. 
The parallel model thus suffers from the 
following disadvantages : it requires more 
therapists and system changes, it is not properly 
operational in larger treatment symptoms, 
tendency for conflicts during treatment can be 
pointed out by patients, it requires broadening 
of knowledge of therapist, the excessive load of 
therapy creates stress on the patient, and overall 
it is cost-inefficient and expensive (Ries, 1993; 
Ries at al., 1997; el-Mallakh, 1998; Mueser et al., 
1998a). 
Thus, because of the numerous problems 
evident in both the serial and parallel treatment 
systems, by the end-1980s and early 1990s 
several authors in the USA started advocating 
some kind of integration' of the mental health 
and addiction treatment approaches to create a 
comprehensive model of care (Osher & 
Kofoed,1989; Rosenthal & Miner, 1997; Ries, 
1993). This amalgam of ideas and programs 
came to be known as an "integrated model" of 
dual diagnosis management. Although specific 
aspects of this model as advocated by these 
different authors differed to some extent, general 
consensus seems to have emerged regarding 
the definition and the essential elements (or 
principles) of this model, which are described 
below (Galanter et al.,1994; Ries et al.,1997; 
Mueser & Fox, 1998; Mercer et al.,1998). 
37 DEBASISH BASU & NITIN GUPTA 
THE INTEGRATED MODEL 
Definition 
The integrated treatment program can be 
defined as a program in which the same clinician 
(or team of clinicians) provides treatment for both 
the mental illness and the substance use disorder 
at the same time (Mueser et al.,1998a). This 
clinician (or team) assumes responsibility for 
integrating the mental health and substance abuse 
treatments so that the interventions are selected, 
modified, combined, and tailored for the specific 
patient Because the educational and prescriptive 
message is integrated, there is no need for the 
patient to reconcile two messages (which is a 
disadvantage with the parallel system described 
earlier) It should be clear that integration does 
not mean simply that two agencies or programs 
merely agree to collaborate 
Elements (principles) of integrated model 
(Mueser et al ,1998a; Mercer et al ,1998) 
Assertive outreach It is needed as dual 
disordered patients are generally noncompliant 
and unmotivated for treatment. Also, it helps to 
address substance abuse as the central de-
stabilizing factor for mental illness and related 
treatment It generally involves active 
intervention with emphasis on outreach and 
practical assistance A method employed is by 
use of "Continuous treatment teams" (Drake et 
al ,1991) which take full responsibility of a small 
group of patients 
Close monitoring : This refers to intensive 
supervision which is required to initiate and 
sustain early treatment Psychopharmacological 
treatments and urine drug tests can be 
supervised Whether voluntary or involuntary, 
this component is the key in the treatment of 
dual diagnosis patients 
Comprehensiveness In this, not just the specific 
manifestations of a disorder, but a wide range of 
skills, activities, relationships and supports are 
addressed This is important for dually-diagnosed 
patients as they are deficient in various issues 
associated with stable recovery 
Stable living situation There is a need for such 
patients to have access to a range of housing 
options that provide safety, freedom from drugs. 
support and companionship. 
Flexibility and Specialization : Clinicians 
specializing in one type of treatment program 
need to adopt and successfully implement 
components of the other treatment program. 
Stages of treatment : Although a stage model 
has more of heuristic service, yet it helps in 
guiding clinicians in planning and deciding what 
interventions are appropriate at a particular point 
in time Hence, the four stages of Osher and 
Kofoed (1989) need to be remembered viz, 
(a) Engagement - developing a trusting 
relationship or working alliance 
(b) Persuasion - helping the patient to perceive 
the adverse consequences of substance use 
in ones' life and to develop motivation for 
recovery 
(c) Active treatment - helping the patient to 
achieve stable recovery 
(d) Relapse prevention - maintain the stable 
recovery 
The long-term perspective : This is important as 
both illnesses have a chronic, relapsing course. 
Treatment generally is spread over years as 
recovery is very unlikely in the first year of 
treatment. 
Optimism : There are high chances of 
demoralization and pessimism developing in the 
patients, family members and treating clinicians. 
Pessimism of the patient can even be taken as 
'poor motivation' by the treating team Hence, 
one should always have hope for recovery. 
Table 1 summarizes the characteristics of 
the three models with respect to the questions 
raised earlier 
Components of integrated model of 
management 
Effective, integrated dual diagnosis 
management includes several components that 
require new expertise and programmatic content 
(eg dual diagnosis assessment, individual 
clinical case management, and group 
intervention) Other components require 
modification of existing services to meet special 
needs of these patients (e.g. pharmacotherapy, 
family interventions, rehabilitation and crisis 
management). Brief notes on some of these 
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TABLE 1 
ISSUES IN DUAL DIAGNOSIS MANAGEMENT : COMPARISON OF THE THREE TREATMENT APPROACHES 
(MODELS) 
Issues 
Which is more "important" 
for treatment: psychiatric 
or substance abuse? 
Which setting is preferred : 
psychiatric or deaddiction? 
Serial 
Depends upon individual concept 
and preference of the treating 
agency 
One after another (patient often 
gets rejected from either) 
What are the ideal principles Control of one disorder followed 
of therapy? 
Who should treat: 
psychiatrist or addiction 
specialist? 
What all treatment 
personnel are needed? 
Funding and administrative 
responsibility 
Are the services provided : 
-> comprehensive? 
-> effective? 
--> cost-efficient? 
by another (often, none occurs 
first) 
One followed by the other 
Those for the usual setting (no 
special or cross discipline 
training required) 
Separate 
Usually not 
not demonstrated 
not demonstrated 
Parallel 
Both 
Both concurrently but separate 
from each other 
Control of both together though 
separately (patient often gets 
contradictory messages) 
Both concurrent but separately 
(as above) 
As in serial 
Separate 
often not 
not demonstrated 
not demonstrated 
Integrated 
Both 
Single setting where 
treatment for both are 
integrated 
See text 
A single person or single 
team (usually led by a 
psychiatrist) 
Psychiatrist, clinical 
psychologist, psychiatric 
social worker (all with cross 
discipline special training) 
Combined 
aims to be 
demonstrated and replicatec 
immediately not (high cost) 
but later becomes efficient 
(more research needed) 
TABLE 2 
A TENTATIVE LIST OF MEDICATIONS PROBABLY USEFUL FOR DUAL DIAGNOSIS PHARMACOTHERAPY 
Psychiatric Disorder 
Schizophrenia 
Bipolar disorder 
Unipolar depression 
/dysthymia 
Anxiety disorders 
Medication 
Clozapine 
Tiapride 
Lithium 
Carbamazeptne 
Imipramine 
SSRIs (esp.fluoxetine) 
Bupropion 
Benzodiazepines 
Buspirone 
TCAs & SSRIs 
Possible benefit 
Alcohol, cocaine 
Alcohol 
Alcohol 
Alcohol 
Alcohol 
Nicotine 
n substance use 
nicotine 
Withdrawal management, 
esp alcohol 
Alcohol 
Alcohol 
Remarks 
Pre-clinical studies; open-label 
studies in humans; controlled 
studies in progress 
Few controlled studies available 
Few controlled studies; contradictory 
reports for lithium, small numbers 
forcarbamazepme 
Double-blind controlled studies; 
modest effect on drinking parameters 
-do-(plus, ?anti-craving effect) 
Double blind controlled studies; need 
replication 
Risky to continue beyond withdrawal 
due to abuse liability 
Non-addictive, controlled studies 
available; modest effect on drinking 
See above 
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follow; lengthier discussions are available 
elsewhere (Galanter et al ,1994; Drake et al., 
1998b; Mueser et al., 1998a, Mercer at al. ,1998). 
Assessment: Accurate assessment of the dual 
diagnosis patients demands techniques that 
differ from those in single diagnosis cases (Carey 
& Correia, 1998), and entails assessment for 
screening, diagnosis and management planning. 
Screening can be done either by collateral 
informants or by self-reports. Regarding the 
former, two 5-point clinician-rating scales, one 
for alcohol use and one for other drug use, have 
been developed The clinician uses all available 
information accumulated over a period of up to 
6 months to make the ratings The Alcohol Use 
Scale and Drug Use Scale (Drake et al ,1996) 
can be completed reliably and correspond with 
more intensive interview-based methods of 
establishing substance abuse diagnoses. 
However, these are useful only for patients who 
are in recent contact with some clinician or 
treatment personnel. In contrast, recently a new 
interviewer - administered but self-report 
screening tool has been developed specifically 
for the identification of substance abuse in 
suspected dual diagnosis patients, named 
Dartmouth Assessment of Lifestyle Instrument 
(DALI; Rosenberg et al.,1998). The preliminary 
report indicates that it is reliable over time and 
across interviewers, and more sensitive and 
specific than standard screening tools such as 
CAGE and MAST 
Diagnostic assessment is often difficult because 
of various complex interrelationships between 
the substance use and psychiatric disorders 
(Mueser et al ,1998b) 
It may be very difficult to distinguish 
schizophrenia from chronic substance induced 
psychoses (Rosenthal & Miner, 1997). Rather 
than concluding prematurely that psychotic 
symptoms are, or are not. substance-induced, 
the integrated model advocates that clinicians 
should initiate treatment of both psychosis and 
substance abuse in uncertain cases (Shaner et 
al ,1998) 
Management planning assessment may be 
facilitated by use of the Substance Abuse 
Treatment Scale (SATS; McHugo et al.,1995). 
Consistent with the Osher and Kofoed's (1989) 
stages of changes model of dual diagnosis 
treatment, the SATS can help the clinician to 
assess the patient's stage of readiness for 
treatment, and plan management accordingly. 
Individual clinical case management : Many 
patients with dual diagnosis are not helped by 
confrontative techniques, the concept of a higher 
power (as in Alcoholics Anonymous) and the 
explanatory model of addiction as an illness that 
is used in conventional substance abuse treatment 
(Mercer et al.,1998). Individual case management 
provides patients with motivational support. 
Motivational counselling gradually fosters a 
trusting relationship with the patient. The clinician 
encourages the patient to identify goals and 
hopes, fosters awareness of discrepancies 
between goals and substance use behaviours, 
guides the patient in developing new skills, and 
supports the patient's growing self-efficacy. This 
has to be done at an individual level, taking into 
account the stage of readiness for change that 
the patient is in at a particular time (Ziedonis & 
Trudeau, 1997). 
Pharmacotherapy : Medications for both 
psychiatric and substance use disorders should 
be integrated with psychosocial interventions in 
a complementary way. Failure to prescribe 
needed medications or undermedication can 
accelerate psychiatric deterioration and/or 
relapse of substance abuse. On the other hand, 
this need to medicate properly must be balanced 
by the caution warranted because of the potential 
risks of prescription abuse (e.g.benzodiazepines) 
and of adverse interactions between medications 
and drugs of abuse (e.g. phenothiazines and 
alcohol). 
In addition, due to the high rate of 
medication non-compliance in dual diagnosis 
patients, close monitoring of medication 
adherence in the community, for example by 
outreach teams, is often desirable. 
The centre for substance abuse treatment 
(Ries,1995) has developed several guidelines 
for integrating pharmacotherapy with 
psychosocial approaches : 
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1. Begin with non-pharmacologic approaches to 
manage emerging symptoms of a less severe 
nature, such as anxiety or mild depression, and 
add medications if the symptoms do not respond. 
At the same time, recognize that acute and 
severe symptoms associated with mania, 
psychotic or severe depression, and 
schizophrenia definitely require medications in 
proper doses. 
2. Encourage the use of medications with a low 
abuse potential: This conservative dictum should 
again be moderated by the dangers of acute and 
severe symptoms. 
3. Be aware of specific interactions between 
drugs of abuse or withdrawal syndromes and 
medication effects. For example, alcohol 
intoxication and withdrawal can disturb 
electrolyte balance and affect lithium levels. 
Specific pharmacotherapies for dual 
diagnosis are only now emerging, e.g. use of 
clozapine for dual diagnosis schizophrenia 
(Buckley, 1998; Lee et al.,1998), fluoxetine or 
imipramine for the depressed alcoholic 
(Cornelius et al.,1997; McGrath et al., 1996). It 
is heartening to note that recent review articles 
in reputed journals on drug therapy for alcohol 
dependence devote an appreciable section on 
dual diagnosis (e.g. Swift, 1999). Table 2 presents 
a tentative (and incomplete) list of such 
medications as are emerging to be specifically 
relevant to dual diagnosis pharmacotherapy. It 
must be conceded that replicated large double-
blind controlled trials are lacking for many of the 
medicines mentioned in the table; however, this 
table may serve as a stimulus for further inquiry 
as well as for empirical treatment currently. 
Finally, Sowers & Golden (1999) have 
focused on psychological factors interplaying 
with attitudes towards taking, or rejecting, 
medications by dual diagnosis patients as well 
as countertransference of physicians influencing 
medication prescriptions. Thus, alongwith 
pharmacokinetic considerations, psychodynamic 
factors also can become relevant in 
pharmacotherapy of dual diagnosis. 
Other components of integrated treatment 
model: Group hterventionsfor substance abuse 
treatment are major components in most dual 
diagnosis treatment programs. Their common 
characteristics are - focus on substance use while 
maintaining their specific sensitivity to the person 
with a severe mental illness (Mueser & Noordsky, 
1996). They commonly provide psychoeducation 
and support, social skills training, stage-wise 
treatment (to engage and persuade patients for 
reducing or stopping substance use), or a 
combination thereof. 
Family support and family psychoeducation 
should again combine elements from both 
psychiatric as well as substance use disorder. 
For example, training for family members can 
prepare them with the skills to recognize signs 
of substance relapse, to manage crises, to 
prevent and manage violent behaviour, to check 
and encourage patients' adherence to 
medication, and to avoid enabling substance use 
(Mueser & Fox, 1998). 
PATIENT-TREATMENT MATCHING : DUAL 
DIAGNOSIS TYPOLOGY 
The above section highlighted the general 
principles, characteristics and components of 
integrated approaches to management of dual 
diagnosis. When it comes to individual patients, 
however, one has to apply certain discretions in 
view of the particular circumstances individually 
relevant to the patients. For example, a patient 
with chronic and severe schizophrenia who also 
abuses alcohol needs to be handled somewhat 
differently from another patient with long-
standing severe alcohol dependence presenting 
currently with a depressive episode Thus, some 
kind of patient-treatment matching' is required 
even within the integrated treatment framework 
keeping in mind the large heterogeneity of this 
population. One way to deal with this situation is 
to evolve a dual diagnosis typology' that can 
classify these patients into clinically meaningful 
subgroups. Only recently have investigators 
started to evolve such typologies, and obviously 
more research is needed in this important area. 
Ries' Typology (Ries et al.,1997) 
This is based on the combination of 
relative severities of psychiatric vis-a-vis 
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substance use disorders, namely. 
Type I: High-severity psychiatric - high - severity-
substance. 
Type II High-severity psychiatric - low - severity-
substance. 
Type III Low-severity psychiatric-high -severity-
substance 
Type IV: Low-severity psychiatric - low - severity-
substance 
Ries et al (1997) explained that 'high-
severity psychiatric' means that the patient has 
a chronic psychiatric disorder causing major 
psychosocial dysfunction (e.g. schizophrenia, 
bipolar disorders, recurrent severe depressive 
disorders, delusional disorder, and schizotypal 
or borderline personality disorders). 'Low-
severity psychiatric' includes uncomplicated 
depression, dysthymia, many anxiety disorders, 
other personality disorders, and substance-
induced psychiatric disorders. 'High-severity 
substance' includes a DSM-IV (or ICD-10) -
diagnosed substance dependence, whereas 
' low-seventy substance' means those who have 
a DSM-IV substance abuse or those with 
substance use that has a measurable but minor 
impact on their psychosocial function Based on 
a combination of these, the four types would 
require individually-tailored management within 
the broad framework of an integrated approach? 
Zimberq's Typology (Zimberq,1999) 
Very recently, a different typology has 
been described, based on the relative 
importance of the two types of disorders, either 
(or none) being considered as primary'. 
Type I : primary psychiatric disorder, with 
substance use only when psychiatrically 
symptomatic (self-medication). 
Type II primary substance use disorder with 
substance-induced psychiatric symptoms. 
Type III psychiatric and substance use disorders 
both of long duration that are co-occurring or 
present at different times (i.e. no 'primary-
secondary' distinction possible). 
The author concedes that the Type III' is 
considered the "true" dual disorder state. This 
typology was found to be reliable and to have 
& NITIN GUPTA 1 
consensual validity. This method was found to 1 
be relatively easy to apply; it also improved staff \ 
interest, differential diagnosis and targeted 
interventions. 
RESEARCH ON INTEGRATED TREATMENT 
OUTCOME 
With the proliferation of integrated 
treatment programs over the past decade, the 
effectiveness of these programs has become the I 
subject of substantial research (Mueser et < 
al.,1997, 1998a; Drake etal., 1998a, el Guebaly, j 
1999; Dixon, 1999). Many of the nearly 40 studies ] 
available to date (mid-1999) are plagued with ] 
small sample sizes, lack of control groups, j 
definitional and operational problems, high drop- ; 
out rates, and difficulty in reliably and validly '• 
recording the various outcomes; especially 
substance use. A recent comprehensive review 
on the subject found that out of 36 reports only 7 ,; 
employed experimental designs, the rest being | 
quasi-experimental or open clinical trials (Drake I 
etal, 1998a). However, there are several trends . 
emerging from this decade-long research output, 
as follows : 
1. The integrated dual diagnosis programs were 
capable of engaging the majority of dually 
diagnosed patients in treatment and retaining 
them in treatment for 1 year or more. 
2. Engagement in programs was associated with 
greater improvement in substance use outcomes 
compared to patients who dropped out. 
3. With several years of treatment, the dual 
diagnosis patients demonstrated a consistent 
gradual progression towards substance use 
reduction and abstinence. Most research on 
traditional (serial or parallel) treatment 
approaches indicates annual rates of sustained 
remission of less than 5%. In comparison, recent 
research on integrated programs suggests 
significantly higher rates of remission, with 
10-20% of these patients achieving stable 
remission per year. These remission rates 
roughly approximate those seen among in 
treatment patients with substance abuse only, 
suggesting that integrated treatment many 
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eliminate the adverse effect of psychiatric 
disorder on remission from substance abuse. 
4. There is also evidence that improvements in 
substance use outcomes are associated with 
gains in a variety of other areas such as 
psychiatric symptoms, stable community days, 
and quality of life (Drake et al.,1998b; el-
Guebaly,1999). Issues on which research data 
are either inadequate, ambiguous or 
contradictory, include : (a) which specific 
modality of treatment is most useful, e.g. 
behavioral skills training, 12 - step program, 
cognitive behavioral therapy etc.; (b) role of 
inpatient treatment, and for how long, in the 
overall patient management; and (c) to what 
extent these research' findings, as summarized 
above, translate themselves into routine' clinical 
care. Also, the patient-treatment matching issues 
remain, as mentioned earlier. 
WHAT ABOUT INDIA? 
Johnson (1997) argued that in the UK and 
Europe, integrated care formulation may be 
easier as treatment for addiction forms part of 
the mental health system. However, due to the 
presence of centralized services with large 
catchment areas, accessibility and delivery of 
care can be problematic. Engagement of patients 
into treatment can be further hampered by 
absence of some of the coercive methods 
available in USA. Another problem faced is that 
published evaluations of specialist services 
rarely make clear how far these coercive 
methods have been used to engage patients in 
treatment. 
In India, the existence of de-addiction and 
mental health systems is either part of each other 
or placed separately though not distinct. Training 
for both services is provided though generally 
the focus is not on specialist de-addiction 
training, especially for the paraprofessional. Also 
there are only a few prevalence studies in this 
area with no mention in literature on the 
management aspects. Hence, there is a serious 
and urgent need to focus, develop, integrate, 
evaluate and finalize management asDects of 
the dually disordered'. Treatment models need 
to be formulated keeping in mind the variations 
in trained personnel, economics and 
commonality of type of disorders encountered. 
In fact, integration of treatment strategies (based 
on the integration model) may be the best 
possible strategy in Indian settings, keeping in 
mind our social, cultural and economic 
background. But this may again prove 
problematic due to the presence of separate 
funding agencies for psychiatric and de-addiction 
facilities at the administrative (government) 
level. 
This review, as hinted at in the beginning, 
aims to be a curtain-raiser. The problems, their 
consequences, and potential solutions being 
worked out elsewhere have been highlighted. 
India is in an advantageous situation since, unlike 
that in USA, the mental health and addiction 
treatment systems are not formally segregated 
here. Many of us, both in the public as well as in 
the private sectors, are perhaps using some of 
the principles of the integrated treatment 
approach already, albeit intuitively. With the 
further enhancement of collective awareness, 
better programmes can be devised and 
implemented for this doubly jeopardized group 
of patients. 
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